Next Article in Journal
Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals
Next Article in Special Issue
3D Printed Pellets (Miniprintlets): A Novel, Multi-Drug, Controlled Release Platform Technology
Previous Article in Journal
Evaluation of a Methylcellulose and Hyaluronic Acid Hydrogel as a Vehicle for Rectal Delivery of Biologics
Open AccessReview

The Digital Pharmacies Era: How 3D Printing Technology Using Fused Deposition Modeling Can Become a Reality

Laboratory of Food, Drugs and Cosmetics (LTMAC), University of Brasília (UnB), Brasília 70910-900, Brazil
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(3), 128; https://doi.org/10.3390/pharmaceutics11030128
Received: 24 February 2019 / Revised: 12 March 2019 / Accepted: 14 March 2019 / Published: 19 March 2019
(This article belongs to the Special Issue 3D Printing of Pharmaceuticals and Drug Delivery Devices)
The pharmaceutical industry is set to join the fourth industrial revolution with the 3D printing of medicines. The application of 3D printers in compounding pharmacies will turn them into digital pharmacies, wrapping up the telemedicine care cycle and definitively modifying the pharmacotherapeutic treatment of patients. Fused deposition modeling 3D printing technology melts extruded drug-loaded filaments into any dosage form; and allows the obtainment of flexible dosages with different shapes, multiple active pharmaceutical ingredients and modulated drug release kinetics—in other words, offering customized medicine. This work aimed to present an update on this technology, discussing its challenges. The co-participation of the pharmaceutical industry and compounding pharmacies seems to be the best way to turn this technology into reality. The pharmaceutical industry can produce drug-loaded filaments on a large scale with the necessary quality and safety guarantees; while digital pharmacies can transform the filaments into personalized medicine according to specific prescriptions. For this to occur, adaptations in commercial 3D printers will need to meet health requirements for drug products preparation, and it will be necessary to make advances in regulatory gaps and discussions on patent protection. Thus, despite the conservatism of the sector, 3D drug printing has the potential to become the biggest technological leap ever seen in the pharmaceutical segment, and according to the most optimistic prognostics, it will soon be within reach. View Full-Text
Keywords: digital pharmacy; fused deposition modeling 3D printing; modified drug release; personalized medicines; telemedicine digital pharmacy; fused deposition modeling 3D printing; modified drug release; personalized medicines; telemedicine
Show Figures

Graphical abstract

MDPI and ACS Style

Araújo, M.R.P.; Sa-Barreto, L.L.; Gratieri, T.; Gelfuso, G.M.; Cunha-Filho, M. The Digital Pharmacies Era: How 3D Printing Technology Using Fused Deposition Modeling Can Become a Reality. Pharmaceutics 2019, 11, 128.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop